This was based on the KEYNOTE-024 phase III trial, which found that in advanced NSCLC, pembrolizumab as a first-line treatment in patients with >50% of PD-L1 positive tumour cells achieved an improved overall survival (5.2 months vs 4.1 months) and ORR (44.8% vs. 27.8%) in comparison to platinum-based chemotherapy [34]. The gene discussed is CD274; the disease is neoplasm.